ELOCTA (efmoroctocog alfa), factor VIII

No clinical benefit demonstrated by comparison with other coagulation factor VIII products in the treatment and prophylaxis of bleeding in patients with haemophilia A

• ELOCTA has Marketing Authorisation in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). It is indicated in all age groups.
• It is a recombinant FVIII with an extended half-life
• In the absence of direct comparison, the studies do not allow a conclusion about its possible benefit compared with other available FVIIIs in reducing bleeding or frequency of injections, especially in young children.